Lexicon Pharmaceuticals Announces Upcoming Investor Conferences
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) has made an exciting announcement about its participation in two key investor conferences scheduled for December. The CEO, Mike Exton, will represent the company and share its vision and progress with potential investors and stakeholders.
Conference Presentations and Details
These gatherings are excellent opportunities for Lexicon to connect with the investment community, discussing its strategic goals and milestones. The specifics are as follows:
Piper Sandler Annual Healthcare Conference
On December 3, 2024, at 8:00 am ET, Lexicon will present at the Piper Sandler 36th Annual Healthcare Conference. This presentation will focus on the company’s advancements and future plans. Attending this event is crucial for investors keen on understanding the innovations Lexicon is working on.
Evercore HealthCONx Conference
Following that, on December 5, 2024, at 12:30 pm ET, Lexicon will also feature at the Evercore HealthCONx Conference. This presentation will give another platform to showcase the company's pioneering efforts and inviting dialogue with those interested in pharmaceutical advancements.
Webcast Availability
For those unable to attend in person, Lexicon ensures the presentations will also be accessible via simultaneous webcasts. These can be found in the 'Events' section of the Lexicon website. A recording of both sessions will be available for two weeks afterward, allowing wider access to the information shared during the conferences.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals is dedicated to pioneering medicines that have the potential to transform patients' lives. Central to their mission is the Genome5000™ program, an innovative genomics target discovery platform that has enabled scientists at Lexicon to explore nearly 5,000 genes. From this rigorous study, they have pinpointed over 100 protein targets showing significant therapeutic promise across various diseases.
Focused on neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity, metabolism, and other areas, Lexicon's pipeline is filled with potential drug candidates that are currently in various stages of discovery and development. This commitment is aimed at developing safe and effective treatments for pressing health issues.
Staying Updated
For updates and more information about their developments, the company encourages interested parties to visit their official website. Lexicon keeps open lines of communication for investors and media, enabling the community to stay informed about their progress and future initiatives.
Frequently Asked Questions
What is the purpose of the December investor conferences?
The conferences allow Lexicon Pharmaceuticals to present their advancements and strategic goals, providing information to current and potential investors.
Who will represent Lexicon at the conferences?
Mike Exton, the CEO of Lexicon Pharmaceuticals, will be presenting at both investor conferences.
Where can I view the presentations?
The presentations will be available through webcasts on the Lexicon website in the 'Events' section and will be recorded for later viewing.
What is the Genome5000™ program?
It is Lexicon's unique genomics target discovery platform aimed at studying the role of a vast array of genes to find therapeutic targets for various diseases.
How can I contact Lexicon Pharmaceuticals for more inquiries?
Inquiries can be directed to their investor relations email at lexinvest@lexpharma.com for further information and questions regarding the company.
